H.C. Wainwright lowered the firm’s price target on Apellis (APLS) to $45 from $57 and keeps a Buy rating on the shares following the Q3 report. The firm says Syfovre’s softer Q3 performance “warrants further tracking.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings
- Apellis Pharmaceuticals: Strong Market Position and Growth Potential Amidst Challenges
- Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis Pharmaceuticals
- Apellis price target lowered to $27 from $29 at BofA
- Apellis falls -24.8%